IFNG-AS1 and MAF4 long non-coding RNAs are upregulated in acute leukemia patients who underwent bone marrow transplantation

Jafari, Leila; Izadirad, Mehrdad; Vatanmakanian, Mousa; Ghaedi, Hamid; Farsiani, Mehdi Allahbakhshian; Mohammadi, Mohammad Hossein; Amiri, Vahid; Hosseini, Maryam Sadat; Tavakoli, Farzaneh; Азизян, Р. И.; Gharehbaghian, Ahmad; Hajifathali, A.

doi:10.1016/j.retram.2021.103307

Cited by 10 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although most pediatric ALL patients respond well to chemotherapy, the outcome becomes less favorable when patients relapse. Cytogenetic alterations are common, and some molecular markers have been recognized to predict the prognosis [ 47 , 48 ]. Researches revealed that chromosomal translocations that appear prenatally are the primary event in multistage leukemia development.…”

Section: Introductionmentioning

confidence: 99%

Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment

et al. 2021

View full text Add to dashboard Cite

Chromosomal translocations are the main etiological factor of hematologic malignancies. These translocations are generally the consequence of aberrant DNA double-strand break (DSB) repair. DSBs arise either exogenously or endogenously in cells and are repaired by major pathways, including non-homologous end-joining (NHEJ), homologous recombination (HR), and other minor pathways such as alternative end-joining (A-EJ). Therefore, defective NHEJ, HR, or A-EJ pathways force hematopoietic cells toward tumorigenesis. As some components of these repair pathways are overactivated in various tumor entities, targeting these pathways in cancer cells can sensitize them, especially resistant clones, to radiation or chemotherapy agents. However, targeted therapy-based studies are currently underway in this area, and furtherly there are some biological pitfalls, clinical issues, and limitations related to these targeted therapies, which need to be considered. This review aimed to investigate the alteration of DNA repair elements of C-NHEJ and A-EJ in hematologic malignancies and evaluate the potential targeted therapies against these pathways.

show abstract

Section: Introductionmentioning

confidence: 99%

Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Recent evidence indicates that lncRNAs affect GvHD occurrence by regulating these cells. Lnc‐MAF4 and IFNG‐AS1 are related to IFNγ production and TH1 cell differentiation, and they were found to be higher in acute GvHD patients at day 28 and 52 ± 8 when compared to non‐GvHD patients 93 . The same group also found higher lnc‐DC levels at day 28 after HSCT in patients with a GvHD than non‐GvHD patients 94 .…”

Section: Lncrnas Regulate Hematopoietic Stem Cell Transplantation Out...mentioning

confidence: 86%

Long non‐coding RNAs regulate treatment outcome in leukemia: What have we learnt recently?

Shi

Gao

Zhang³

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Increased expression of IFNG-AS1 could facilitate HP75 cell proliferation, cell invasion, migration, and suppressed cell apoptosis in pituitary adenomas by regulating epithelial splicing regulatory protein 2 (ESRP2) [ 14 ]. A recent study demonstrated that IFNG-AS1 expression was increased in acute leukemia patients who received bone marrow transplantation [ 32 ]. In this study, the silence of IFNG-AS1 weakened HT-29 and SW480 cell viability, migration, and invasion of colon adenocarcinoma, suggesting that IFNG-AS1 may be an oncogene in colon adenocarcinoma.…”

Section: Discussionmentioning

confidence: 99%

Significance of long non-coding RNA IFNG-AS1 in the progression and clinical prognosis in colon adenocarcinoma

Wang

Cao

Wang³

2021

Bioengineered

View full text Add to dashboard Cite

Colon adenocarcinoma originates from adenoma and triggers serious healthy burdensome. lncRNAs develop a crucial role in the progression of colorectal carcinoma. In this study, we aimed to investigate the clinical value and potential role of lncRNA interferon (IFN) gamma antisense RNA 1 (IFNG-AS1) in colon adenocarcinoma. This study enrolled 95 colorectal adenoma patients, 128 colorectal adenocarcinoma patients, and 88 healthy individuals. The serum, tissue IFNG-AS1 expression levels were explored by real-time quantitative reverse transcription-PCR (RT-qPCR) assay. The receiver operator characteristic curve and Kaplan-Meier method were used to assess the clinical significance of IFNG-AS1. The chi-square test was used to analyze the association between tissue IFNG-AS1 and clinical characteristics. Functional experiments were conducted to delve into the effects of IFNG-AS1 on cellular activities (cell viability/migration/invasion). The target miRNA of IFNG-AS1 was also explored. IFNG-AS1 expression in both serum and tissue samples was elevated in patients. Serum IFNG-AS1 could diagnose colon adenoma and adenocarcinoma patients from the healthy control. High tissue IFNG-AS1 was correlated with several clinical characteristics and a shorter overall survival time. Silence of IFNG-AS1 could be available for repressing cellular capacities via the sponge to miR-627-3p. IFNG-AS1 was rised in colon adenocarcinoma and it was relevant to tumor size, TNM stage, and poor prognosis of patients. Beyond that, downregulated expression of IFNG-AS1 may repress malignant progression of colon adenocarcinoma by regulating miR-627-3p. IFNG-AS1 might be a potential diagnosis or prognosis predictor for colon adenocarcinoma patients.

show abstract

IFNG-AS1 and MAF4 long non-coding RNAs are upregulated in acute leukemia patients who underwent bone marrow transplantation

Cited by 10 publications

References 26 publications

Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment

Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment

Long non‐coding RNAs regulate treatment outcome in leukemia: What have we learnt recently?

Significance of long non-coding RNA IFNG-AS1 in the progression and clinical prognosis in colon adenocarcinoma

Contact Info

Product

Resources

About